Latest News

  • diagnostics

Work begins on Liverpool’s £20m Rutherford Diagnostics HQ

Work began on Liverpool’s new £20 million Rutherford Diagnostics headquarters yesterday (8 January).

A turf-cutting event took place at the Paddington Village plot for the advanced Proton Partners International healthcare facility, which will be the first in a network of centres.

The centre is being built yards from where work to build the Rutherford Cancer Centre North West is already underway, as Rutherford Diagnostics works towards its goal of reducing waiting times for diagnostic tests from weeks to days and developing partnerships with private healthcare and NHS organisations to achieve it.

At the heart of Rutherford Diagnostics will be genomics, the recording of whole genome sequence data which will be used to predict disease, susceptibility, and treatment and drug response.

Proton Partners International’s CEO, Mike Moran attended the ceremony alongside Mayor of Liverpool Joe Anderson; Professor Dame Janet Beer, vice-chancellor of the University of Liverpool and chair of Knowledge Quarter Liverpool; and Rutherford Diagnostics’ chief diagnostic officer, Dr Steven Powell.

Commenting on the five-storey centre, which is being built by the council’s appointed contractor Morgan Sindall, Mayor Anderson said: “This diagnostics centre is going to be a fantastic addition to Paddington Village and further boosts our plans for a world leading innovation hub in the heart of the city’s Knowledge Quarter.

“Paddington Village is gaining real momentum now with renowned tenants like Proton Partners International, the Royal College of Physicians and Kaplan investing in the city and creating highly skilled jobs – and the great news is that there is much more to come.”

Moran added: “Once complete this centre will represent a true step change in the way diseases are detected and treated. Britain’s approach to healthcare is unfortunately very reactionary, often responding to diseases when they have reached an advanced stage.

“We hope to turn that around using personalised screening and advanced diagnostic technologies.”